address talk me let question first. So -- the first
the we those you also the X reason, our about we read groups. So dose use the XX-milligram talk and group XX-milligram are that description arms when or presentation, for group. dose expression the groups, And
the We titration X X those as that of those to the the -- allow as tolerated Placebo, each target best to close at dose the for was patients we relatively since end dose day, way. arms. other realize arms So by most for the the basically in well
XX XX-milligram were in while milligrams, group, So with with there the some some also were they XX.
much. So it not by than higher bit but the XX-milligram was group, a
they analysis. also prespecified together against close. And much a arms pretty in are placebo why X the So that's predefined we
the was that background. So
in a curve we Phase So IIa. dose to our have seen response prior that
where to we about we So and to now what confirmed. X we is and question, noticed the we the in that's no -- X [indiscernible] where trial force was coming But -- quickly of noticed that then is dose patients weeks, part well we to the there's to where doubt dose received. this second very didn't weeks notice XX uptake that within very the response trade
And about this. are didn't we early Some well. COVID, Alzheimer. feel of felt continue patients, patients COVID. impaired dizziness. the of course, don't then some maybe comfortable during they're have because as not we so to they It saying, was time had it, I want They
that's in at dose dropouts dose group. So we some lower more the the had why higher than
allowing study So also less patients in what force take we in stringent a more, would instead the open-label morning, take did to we drug basically during way the when trial morning. which realize I and the allowed at we lenient the patients to the of we early titration up say, of night now time and where
tolerance XX titrate period compassionate that time. and we or do noticed were with long taking have this they to dose, XX XX that as as to noticed long enough in get there program higher where the drug or also high also to then tolerance time extremely of XX much as they was patients use And dosing. used allowing we a nighttime for longer the allowed So to it for as either
of we because percentage how brain which XX matter the dose. don't drug, you brain And like with adverse don't events look have seen more that that always effects of antibody, a It's bleeding we side and at titrate the dangerous that trial target addressable actually to So have adverse manageable from the will we event. no clearly -- we don't to or of we manifestation swelling you have, force a we antibodies, it's to in so them basically also quickly you point up have. out a see not patients take have a drug an of the this or which when very
manageable on of our in will, a be because case, titration can the in event just changed, why fixable, and But the that's future. it's that do of we is and now schedule, the dependent one course, adverse dizziness
the disease, again, had And and that. say that's we knowledge So we've also, answer from that question. are heard to that to the also needless that that not your physicians patients all --
We shows last for the perspective brain this sometimes also happening in it, average. a is like in had brain. have between And point was I'd to something XX and it's the also shows that relatively make to dizziness that that in put the really who in days one X penetration sign to short lasted those patients that
and -- form very a it's So mild dizziness. a of
to to and learned patients situation. up we that. address So again, But it's it doses easy very quickly, very this in can because, avoid trial a forced high lesson that these we shows we a go to
